Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

HONG KONG (AP) — Asian stocks were mixed Wednesday followed Wall Street’s mostly positive performance ahead of key U.S.

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

With the close of 2024 and the launch of a new year, we can take a moment to look back at what was another eventful, ...

As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...

U.S. stock futures were marginally higher on Monday night after the S&P 500 and Nasdaq Composite notched a second winning day ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...

While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been ... listed the shortage as resolved. Lilly, for its part, has resolved its Mounjaro and Zepbound shortages ...